WILSON SONSINI

Tina Xiang

PATENT AGENT

Patents and Innovations

New York

txiang@wsgr.com
212-453-2819

FOCUS AREAS

Intellectual Property

Life Sciences

Patents and Innovations

EXPERIENCE

Dr. Tina Xiang is a patent agent in the New York office of Wilson Sonsini Goodrich & Rosati. She has experience in the fields of cancer biology, targeted therapy, genetics, and cellular and molecular biology. Tina applies her experience to patent prosecution, freedom-to-operate, and due diligence matters for clients in the life sciences, pharmaceutical, biotechnology, diagnostics, and medical devices industries.

Prior to joining the firm, Tina completed her doctorate degree at Columbia University. Her dissertation focused on the development of subtype-specific targeted therapy for Muscle-Invasive Bladder Cancer. While at Columbia, Tina was also a fellow at Columbia Technology Ventures, the university's technology transfer office.

Tina is proficient in Mandarin and knowledgeable in German.

CREDENTIALS

Education

- Ph.D., Pathobiology and Mechanisms of Disease, Columbia University, 2022
  Recipient, NIDDK Endocrinology Training Grant
- B.S., Biology, University of North Carolina at Chapel Hill, 2017
  Double Minors in Chemistry and German, With Highest Distinction, Phi Beta Kappa

Admissions

- U.S. Patent and Trademark Office

INSIGHTS

Select Publications

- Co-author, "Development regeneration and tumorigenesis of the urothelium," 149(9) *Development,* 2022
- Co-lead author, "Pparg signaling controls bladder cancer subtype and immune exclusion," 12(1) *Nat. commun* 6160, 2021
- Co-author, "Pparg promotes differentiation and regulates mitochondrial gene expression in bladder epithelial cells," 10(1) *Nat. commun* 4589, 2019

TECHNICAL FLUENCY

Biological Sciences and Biotechnology

- Antibody

- Antigen presentation
- Cancer biology
- Cancer therapeutics
- CAR-T cells
- Cell biology
- Cell therapy
- Cellular immunology
- Epigenetics
- Genetics
- Immuno-oncology
- Molecular biology
- Molecular genetics
- Stem cell biology

Therapeutics and Drug Discovery

- Gene editing
- Gene therapy
- Immunotherapy targets